NASDAQ:OMGA

Omega Therapeutics (OMGA) Stock Forecast, Price & News

$2.30

+0.05 (+2.22%)

(As of 09/28/2023 ET)

Compare

Today's Range: $2.14
▼
$2.37
50-Day Range: $2.25
▼
$5.68
52-Week Range: $2.11
▼
$11.98

Volume: 73,927 shs
Average Volume: 122,363 shs
Market Capitalization: $126.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Omega Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 378.3% Upside
$11.00 Price Target
Short Interest: Bearish
10.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.61
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.14) to ($2.18) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Omega Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, Omega Therapeutics has a forecasted upside of 378.3% from its current price of $2.30.
Amount of Analyst Coverage
Omega Therapeutics has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
10.08% of the float of Omega Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Omega Therapeutics has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Omega Therapeutics has recently increased by 4.88%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Omega Therapeutics does not currently pay a dividend.
Dividend Growth
Omega Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OMGA.

2.6

News and Social Media Coverage

News Sentiment
Omega Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Omega Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for OMGA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
4 people have added Omega Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Omega Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
57.00% of the stock of Omega Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.68% of the stock of Omega Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Omega Therapeutics are expected to decrease in the coming year, from ($2.14) to ($2.18) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Omega Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Omega Therapeutics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Omega Therapeutics has a P/B Ratio of 1.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Omega Therapeutics (NASDAQ:OMGA) Stock

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OMGA Price History

30 days | 90 days | 365 days | Advanced Chart

OMGA Stock News Headlines

September 28, 2023 | markets.businessinsider.com

Promising Preliminary Data and Novel Mechanism of Omega Therapeutics’ OTX-2002 Bolster Analyst’s Buy Rating

September 26, 2023 | markets.businessinsider.com

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

September 28, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 26, 2023 | finance.yahoo.com

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

September 25, 2023 | finance.yahoo.com

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

September 24, 2023 | barrons.com

Omega Therapeutics Inc.

September 2, 2023 | msn.com

HC Wainwright & Co. Reiterates Omega Therapeutics (OMGA) Buy Recommendation

August 7, 2023 | markets.businessinsider.com

Piper Sandler Keeps Their Buy Rating on Omega Therapeutics (OMGA)

September 28, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

August 5, 2023 | finance.yahoo.com

Omega Therapeutics Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags

August 3, 2023 | finance.yahoo.com

Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue Estimates

August 3, 2023 | finance.yahoo.com

Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

July 20, 2023 | finance.yahoo.com

Recursion (RXRX) Stock Surges 191% in 3 Months: Here's Why

July 19, 2023 | msn.com

Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why

July 18, 2023 | finance.yahoo.com

Corcept's (CORT) Early-Stage Study on NASH Reveals Positive Data

July 16, 2023 | finance.yahoo.com

OMGA - Omega Therapeutics, Inc.

July 12, 2023 | uk.news.yahoo.com

Bristol Myers (BMY) Reports Positive Data From Urothelial Cancer Study

July 12, 2023 | msn.com

ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study

July 12, 2023 | finance.yahoo.com

Omega Therapeutics Appoints Chris Schade to its Board of Directors

June 6, 2023 | msn.com

HC Wainwright & Co. Reiterates Omega Therapeutics (OMGA) Prior Recommendation

June 6, 2023 | finance.yahoo.com

Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails

May 31, 2023 | finance.yahoo.com

Ashvattha Therapeutics Expands Leadership Team with Appointment of Paul E. Cayer as Chief Financial Officer and Mahesh Karande to the Board of Directors

May 31, 2023 | finance.yahoo.com

Omega Therapeutics Presents New Preclinical Data Demonstrating the Potential of Omega Epigenomic Controllers™ to Synergize with Immunotherapies at the ASCO 2023 Annual Meeting

May 25, 2023 | finance.yahoo.com

Wall Street Analysts See a 59.64% Upside in Omega Therapeutics, Inc. (OMGA): Can the Stock Really Move This High?

May 25, 2023 | markets.businessinsider.com

Jefferies Reaffirms Their Buy Rating on Omega Therapeutics (OMGA)

May 10, 2023 | seekingalpha.com

Omega Therapeutics: 2023 Could Well Be A Turning Point

May 10, 2023 | finance.yahoo.com

Investors in Omega Therapeutics (NASDAQ:OMGA) have seen impressive returns of 177% over the past year

See More Headlines

Receive OMGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OMGA Company Calendar

Last Earnings: 8/03/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OMGA
CUSIP: N/A
CIK: 1850838
Web: www.omegatherapeutics.com
Phone: 617-949-4360
Fax: N/A
Employees: 116
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.00
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +378.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-102,700,000.00
Net Margins: -4,283.72%
Pretax Margin: -4,283.72%
Return on Equity: -97.34%
Return on Assets: -63.64%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 3.71
Quick Ratio: 3.71

Sales & Book Value

Annual Sales: $2.07 million
Price / Sales: 61.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.21 per share
Price / Book: 1.04

Miscellaneous

Outstanding Shares: 55,140,000
Free Float: 23,710,000
Market Cap: $126.82 million
Optionable: Not Optionable
Beta: 0.74

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Mahesh Karande (Age 49)
Pres, CEO & Board Director
Comp: $812.88k

Ms. Ling Zeng Esq. (Age 54)
J.D., Chief Legal & Admin. Officer and Sec.
Comp: $519.36k

Dr. Yan Moore M.D. (Age 56)
Chief Medical Officer
Comp: $1.14M

Mr. Joshua Reed M.B.A. (Age 50)
Chief Financial Officer

Dr. Sivakesava Sakhamuri Ph.D.
Sr. VP and Head of Technical Operations & Quality

Dr. Thomas McCauley (Age 54)
Chief Scientific Officer

Mr. Charles O'Donnell Ph.D.
VP and Head of Computational Genomics & Data Sciences

Ms. Ramola Bhandarkar
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMGA Stock - Frequently Asked Questions

Should I buy or sell Omega Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares.
View OMGA analyst ratings or view top-rated stocks.
What is Omega Therapeutics' stock price forecast for 2023?: 4 analysts have issued 1 year price objectives for Omega Therapeutics' stock. Their OMGA share price forecasts range from $10.00 to $12.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 378.3% from the stock's current price.
View analysts price targets for OMGA or view top-rated stocks among Wall Street analysts.
How have OMGA shares performed in 2023?: Omega Therapeutics' stock was trading at $5.71 on January 1st, 2023. Since then, OMGA shares have decreased by 59.7% and is now trading at $2.30.
View the best growth stocks for 2023 here.
When is Omega Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our OMGA earnings forecast.
How were Omega Therapeutics' earnings last quarter?: Omega Therapeutics, Inc. (NASDAQ:OMGA) released its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.03. The firm had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.63 million. Omega Therapeutics had a negative trailing twelve-month return on equity of 97.34% and a negative net margin of 4,283.72%.
When did Omega Therapeutics IPO?: (OMGA) raised $126 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share.

What is Omega Therapeutics' stock symbol?: Omega Therapeutics trades on the NASDAQ under the ticker symbol "OMGA."
Who are Omega Therapeutics' major shareholders?: Omega Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.92%), Platinum Investment Management Ltd. (1.61%), 683 Capital Management LLC (0.86%), Geode Capital Management LLC (0.80%), State Street Corp (0.71%) and Northern Trust Corp (0.37%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young.
View institutional ownership trends.
How do I buy shares of Omega Therapeutics?: Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Omega Therapeutics' stock price today?: One share of OMGA stock can currently be purchased for approximately $2.30.
How much money does Omega Therapeutics make?: Omega Therapeutics (NASDAQ:OMGA) has a market capitalization of $126.82 million and generates $2.07 million in revenue each year. The company earns $-102,700,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis.
How many employees does Omega Therapeutics have?: The company employs 116 workers across the globe.
How can I contact Omega Therapeutics?: Omega Therapeutics' mailing address is 20 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.omegatherapeutics.com. The company can be reached via phone at 617-949-4360 or via email at argotomega@argotpartners.com.

This page (NASDAQ:OMGA) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial